

Faculty

Chairs:

Professor Werner Hacke
University of Heidelberg
Heidelberg, Germany

Professor Keith Fox
University of Edinburgh
Edinburgh, UK

Speakers:

Professor Werner Hacke
University of Heidelberg
Heidelberg, Germany

Professor Bo Norrving
University of Lund
Lund, Sweden

Professor Keith Fox
University of Edinburgh
Edinburgh, UK

Organized by Bayer HealthCare Pharmaceuticals

The marketing authorization for rivaroxaban may vary from country to country. In Germany, rivaroxaban is approved for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.

© Bayer HealthCare Pharmaceuticals 2011



Challenging the Threat of Stroke Head On:

Advances in oral anticoagulation

Chaired by Werner Hacke and Keith Fox

Wednesday 25 May 2011, 12:30–14:00

Lunch boxes will be served from 12:15

Room B, Congress Center Hamburg, Hamburg, Germany

A Satellite Symposium organized by Bayer HealthCare Pharmaceuticals
at the European Stroke Conference 2011, Hamburg, Germany
24–27 May 2011

BHP00363/0411 G.G.M.X.A.05.2011.0028



Chairmen's Welcome

Dear Colleagues,

We are delighted to invite you to attend the Satellite Symposium on Advances in Oral Anticoagulation at the European Stroke Conference 2011 sponsored by Bayer HealthCare Pharmaceuticals. The session will address the challenges faced in stroke prevention and management in atrial fibrillation (AF) as well as providing an informative overview of recent clinical study data for the novel oral anticoagulant rivaroxaban for the prevention of AF-related stroke.

AF is a common cause of cardioembolic stroke. With the prevalence of AF projected to double by the mid-21st Century, clinicians need to be aware of the many challenges it brings, in order to improve patient outcomes and reduce the social and economic toll of AF-related stroke. The need for effective and safe therapies remains one such challenge. While treatment with vitamin K antagonists such as warfarin has proven effective in the prevention of AF-related stroke, warfarin is associated with significant shortcomings that substantially limit its clinical utility. Novel oral anticoagulants, either in various stages of clinical development or approved for certain indications, may represent the next generation of anticoagulants for the management of thromboembolic disease. Encouraging data from the recent double-blind phase III ROCKET AF study of rivaroxaban raise the distinct prospect of a new therapeutic option for the prevention of stroke in AF patients.

The educational objectives of this session will provide neurologists with an understanding of:

- ◆ The clinical and healthcare burden of AF-related stroke
- ◆ Primary and secondary prevention strategies in AF-related stroke and their associated clinical challenges
- ◆ Key outcomes from the pivotal phase III ROCKET AF trial
- ◆ Most recent data from ROCKET AF in patients with AF and prior cerebrovascular disease

It will be our great pleasure to welcome you to the 2011 Symposium and we trust that you will have a rewarding time in both the sessions and the discussions.

Kind regards,



Werner Hacke



Keith Fox

Programme

Chaired by Werner Hacke and Keith Fox

Wednesday 25 May 2011, 12:30–14:00

Room B, Congress Center Hamburg, Hamburg, Germany

- 12:30 Welcome and introduction**
Werner Hacke, Germany
- 12:35 Atrial fibrillation-related stroke: implications and challenges**
Bo Norrving, Sweden
- 12:55 Rivaroxaban for stroke prevention in atrial fibrillation: study results in context**
Keith Fox, UK
- 13:15 Secondary prevention of stroke in atrial fibrillation: results from ROCKET AF**
Werner Hacke, Germany
- 13:35 Panel discussion: practical implications of new study data**
- 13:55 Summary and close**

